跳至主要内容
临床试验/NCT04255446
NCT04255446撤回不适用

An Observational, Controlled, Single Centre Study Validating the Structured Light Plethysmography Against Standard of Care in the Diagnosis and Monitoring of Dysfunctional Breathing

Pneumacare Ltd1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2026年10月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
撤回
发起方
入组人数
60
试验地点
1
主要终点
Estabilsih expected value and dispersion of Structured Light Phlethysmography in Dysfunctional breathing patients

研究概览

简要总结

This is an observational, controlled, single-centre study to validate the Thora3Di™ against standard practice in patients who are undergoing investigation for disproportionate breathlessness. The core methodology involves capturing of data during a short period of measurement of breathing using SLP.

详细描述

Cohort A: This study is a pilot study with four study visits (Screening, Baseline, week 13 and week 26) to generate data to characterise the tidal breathing patterns and parameters with Thora3Di™. Subjects will have a screening visit within 0 to 14 days prior to the first study visit. For each study visit, subjects will be seen in the clinical research facility and have two 5-minute SLP measurements (at rest and on exertion). The SLP measurement should be performed prior to standard lung function tests with minimal impact on clinical time and not change to hospital attendance. Also, each visit subjects will be asked to report concomitant medications and adverse events, and fill several questionnaires forms as outlined in the SOAs.

Cohort B: Healthy subjects will have only one visit for this study. After signing the informed consent form, subjects will undergo two 5-minutes SLP measurements (at rest and on exertion).

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
16 Years 至 75 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •• Cohort A: Any adult who is presenting with controlled disproportionate breathlessness will be considered for inclusion as a diseased subject (with excluded comorbidities as cause of breathlessness e.g. uncontrolled asthma (GINA 2019 guidelines), uncontrolled cardiac disease, ILO).
  • •Cohort B: Any adult who is in good respiratory health will be considered for inclusion as a normal in the study.

排除标准

  • •Subject unable to sit in an upright position for required period
  • •Subjects with significant co morbidities (assessed by the clinician at screening only):
  • •Chest wall or spinal deformity e.g. scoliosis OSA, Apnoea hypopnoea index > 30 (if known)
  • •Any other significant disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participants' ability to participate in the study
  • •BMI > 40
  • •Height > 194 cm
  • •Female participant who is pregnant, lactating or planning pregnancy during the course of the study
  • •Inability to consent/comply with trial protocol

研究组 & 干预措施

Healthy Volunteers

Healthy Volunteers without any respiratory problems age between 16 to 75 will be included.

干预措施: Thora3DiTM (Device)

Dysfunctional Breathing

Patients with Dysfunctional breathing age between 16 to 75 will be included.

干预措施: Thora3DiTM (Device)

结局指标

主要结局

Estabilsih expected value and dispersion of Structured Light Phlethysmography in Dysfunctional breathing patients

时间窗: 26 weeks

Measure SLP parameters during the course of the treatment : Baseline, Week 13 and Week 26 at rest and at exertion

次要结局

  • Establish a relationship between Structured Light Phlethysmography parameters and patient report outcomes addressed.(26 weeks)
  • Establish different SLP parameters between patients with dysfunctional breathing and healthy subjects.(26 weeks)

研究者

发起方
Pneumacare Ltd
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验